Cost Containment, Payer Consolidation Are Irreversible – But Opportunities, Private Equity Investors Say
This article was originally published in The Pink Sheet Daily
Whether or not the Affordable Care Act survives a Supreme Court review, private equity investors see abundant opportunities in the rapidly reforming U.S. healthcare landscape, although buyers’ and sellers’ different views of the future lead to pricing disparities.
You may also be interested in...
CMS has approved 27 Accountable Care Organizations for its first round of Shared Savings Program ACOs, bringing the number of participating organizations to 65 with previous Pioneer and Demonstration programs. It has another 150 applications under review for the July round of approvals.
“The Pink Sheet” highlights intriguing, and perhaps telling, comments by U.S. Supreme Court justices from three days of oral arguments pertaining to the constitutionality of the Affordable Care Act, including the constitutionality of the “individual mandate” for insurance coverage, its severability from other ACA provisions, and whether new Medicaid requirements are an unconstitutional coercion of the states.
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?